Cancer Jab Shows 'Unprecedented' Results

By Catamist AI AI summary

Summarized by Catamist’s AI from other outlets’ reporting and checked for neutrality. Original sources are linked below.

A new triple-action cancer jab, amivantamab, has shown "unprecedented" trial results by completely eradicating tumors in some patients with advanced, treatment-resistant cancers. This innovative injection, which blocks cancer-promoting proteins and activates the immune system, offers significant hope after 15 out of 102 patients experienced full tumor eradication, despite previous treatments failing.

A triple-action cancer jab, amivantamab, has shown "unprecedented" trial results, eradicating entire tumors in some patients, as reported by The Irish Times.
The injection was tested on individuals with advanced cancer, primarily head and neck cancer, that had resisted previous chemotherapy and immunotherapy treatments.
Dramatic changes were observed within weeks, with tumors shrinking or disappearing completely in 43 out of 102 patients, and 15 patients experiencing complete tumor eradication, according to The Guardian.
Professor Kevin Harrington of the Institute of Cancer Research, London, stated that these are "unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy".
The findings of this international trial, spanning 11 countries, will be presented at the American Society of Clinical Oncology (ASCO) conference.
Amivantamab works by blocking proteins (EGFR and MET) that help cancers grow and evade treatment, while also activating the immune system to attack tumors.
Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a very poor prognosis, as noted by The Mirror.